Corvus Pharmaceuticals Inc美股招股说明书(2026-01-23版)

7,900,677 Shares of Common Stock We are offering 7,900,677 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “CRVS.” The last reported sale priceof our common stock on the Nasdaq Global Market on January 21, 2026 was $22.15 per share. We are a “smaller reporting company” as defined under the federal securities laws and, as such, we have elected tocomply with certain reduced reporting requirements for this prospectus supplement and may elect to do so in futurefilings. See “Prospectus Supplement Summary — Implications of Being a Smaller Reporting Company.” Investing in our common stock involves significant risks. See “Risk Factors” on pageS-13of this prospectussupplement, on page5of the accompanying base prospectus, and in the documents incorporated by reference into thisprospectus supplement for a discussion of the factors you should consider before investing in our common stock. (1)See “Underwriting” beginning on pageS-25for additional information regarding underwritingcompensation. We have granted the underwriters an option to purchase up to an additional 1,185,101 shares of our common stockat the public offering price, less underwriting discounts and commissions, for 30days after the date of this prospectussupplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the adequacy or accuracy of this prospectus supplement or the prospectus to which it relates.Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares on or about January 23, 2026. Joint Book-Running Managers Jefferies Goldman Sachs & Co. LLC BookrunnerMizuho Co-ManagerLadenburg Thalmann Prospectus supplement dated January 21, 2026 TABLE OF CONTENTS Prospectus SupplementABOUT THIS PROSPECTUS SUPPLEMENTS-1FORWARD-LOOKING STATEMENTSS-2PROSPECTUS SUPPLEMENT SUMMARYS-4THE OFFERINGS-11RISK FACTORSS-13USE OF PROCEEDSS-17DILUTIONS-18DIVIDEND POLICYS-19DESCRIPTION OF SECURITIES OFFEREDS-20MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERSS-21UNDERWRITINGS-25LEGAL MATTERSS-32EXPERTSS-32WHERE YOU CAN FIND MORE INFORMATIONS-32INCORPORATION BY REFERENCES-32ProspectusABOUT THIS PROSPECTUS1WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE2THE COMPANY4RISK FACTORS5USE OF PROCEEDS6DESCRIPTION OF CAPITAL STOCK7DESCRIPTION OF DEBT SECURITIES13DESCRIPTION OF WARRANTS20DESCRIPTION OF UNITS22GLOBAL SECURITIES23PLAN OF DISTRIBUTION27LEGAL MATTERS29EXPERTS29 ABOUT THIS PROSPECTUS SUPPLEMENT We provide information to you about this offering of shares of our common stock in two separatedocuments that are bound together: (1)this prospectus supplement, which describes the specific detailsregarding this offering and also adds to and updates information contained in the accompanying baseprospectus and the documents incorporated by reference in this prospectus supplement and theaccompanying base prospectus; and (2)the accompanying base prospectus, which provides generalinformation, some of which may not apply to this offering. Generally, when we refer to this “prospectus,”we are referring to both documents combined. If information in this prospectus supplement is inconsistentwith the accompanying base prospectus or in any document incorporated by reference that was filed withthe Securities and Exchange Commission (“SEC”) before the date of this prospectus supplement, you shouldrely on this prospectus supplement. However, if any statement in one of these documents is inconsistentwith a statement in another document having a later date — for example, a document incorporated byreference in this prospectus supplement — the statement in the document having the later date modifies orsupersedes the earlier statement as our business, financial condition, results of operations and prospects mayhave changed since the earlier dates. Neither we nor the underwriters have authorized anyone to provide you with any information or tomake any representations other than those contained or incorporated by reference in this prospectussupplement and the accompanying base prospectus or in any free writing prospectus prepared by or onbehalf of us or to which we have referred you. Neither we nor the underwriters take responsibility for, orprovide assurance as to the reliability of, any other information that others may give you. You shouldassume that the information appearing in this prospectus supplement, the accompanying base prospectus,the documents incorporated by reference into this prospectus supplement and the accompanying baseprospectus, and in any free writing prospectus that we may authorize for use in connection with thisoffering, is accurate only as of the date of those respective documents, regardless of the time of delivery ofthis prospectus supplement or any shares of our common stock. Our business, financial condition, results ofoperations and pr